Identification of specific, cell-surface markers of residual HIV infection is a top research priority. We studied CD30 (TNF superfamily receptor) and CD32 expression in blood and gut-associated lymphoid tissue (GALT), determined the HIV burden within CD4+ T cells expressing these markers, and evaluated response to ex vivo anti-CD30 therapy.
CD4+ T cells from blood or gut tissue were sorted based on expression of CD30 and CD32 followed by quantification of cell-associated HIV-1 DNA and RNA. In situ HIV RNA hybridization studies were performed on GALT, and PBMC from ART-suppressed individuals were co-cultured in the presence of the cytotoxic antibody-drug-conjugate, brentuximab vedotin, an approved cancer therapy that targets CD30.
Overall, the frequency of CD30 expressing peripheral CD4+ T cells was significantly higher in ART suppressed (n=17; P=0.002) and viremic (N=9; P=0.045) individuals compared to HIV-uninfected controls. CD30+ T cells expressed higher levels of HLA-DR, CD69 and PD1, although very few activated CD4+ T cells expressed CD30. Cell-associated HIV-1 RNA was significantly enriched in CD30 expressing peripheral CD4+ T cells from ART suppressed (n=17; P=0.008) and viremic participants (n=9; P=0.007). Despite the rarity of CD30+ T cells (<4% of CD4+ T cells), an average of 21% and 28% of HIV-1 RNA burden was attributed to CD30+ cells in suppressed and viremic groups. >90% of detectable cell-associated HIV-1 RNA was found within CD30+CD4+ T cells in samples from 5 individuals, and >50% of cell-associated HIV-1 DNA was attributed to CD30+CD4+ T cells from 3 participants on ART. Interestingly, HLA-DR expression in gut CD4+ T cells was highest in dual CD30+CD32+ expressing cells. Despite the finding that only 0.1% of GALT cells expressed CD30+ RNA determined by in situ hybridization, 88% of all HIV-1 RNA+ cells from ART-suppressed participants expressed CD30 RNA. 78% of HIV RNA+ GALT cells from suppressed individuals expressed CD32, but 80% of GALT cells expressed CD32 in uninfected controls. Finally, ex vivo treatment with brentuximab vedotin, significantly reduced the mean level of HIV-1 DNA in PBMC obtained from seven ART-suppressed individuals (Figure 1).
Our results suggest that CD30+ expression appears to be a marker of residual HIV-1 transcriptional activity in the setting of suppressive ART and that targeting CD4+ T cells from ART-suppressed individuals may reduce overall HIV DNA burden.